Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 16/20 | 0.77 |
| ▸ | ERBB2 | P04626 | 13/20 | 0.77 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.74 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.74 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.74 |
| ▸ | ROS1 | P08922 | 1/20 | 0.74 |
| ▸ | FLT3 | P36888 | 1/20 | 0.74 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.74 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.74 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.60 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3324380 | 0.99 | EGFR (0.76) | EGFRERBB2AURKBERBB4CHEK2 | |
| Hydrochloric Acid SCHEMBL7498317 | 0.93 | EGFR (0.67) | EGFRERBB2AURKBERBB4CHEK2 | |
| SCHEMBL3014295 | 0.88 | EGFR (0.63) | EGFRERBB2AURKBERBB4CHEK2 | |
| SCHEMBL3322166 | 0.88 | EGFR (0.61) | EGFRERBB2AURKBERBB4CHEK2 | |
| Hydrochloric Acid SCHEMBL3704389 | 0.87 | EGFR (0.62) | EGFRERBB2AURKBERBB4CHEK2 | |
| SCHEMBL8363497 | 0.87 | EGFR (1.00) | EGFRERBB2AURKBERBB4CHEK2 | |
| SCHEMBL7243965 | 0.87 | EGFR (0.79) | EGFRERBB2AURKBERBB4CHEK2 | |
| SCHEMBL1387147 | 0.87 | EGFR (0.79) | EGFRERBB2AURKBERBB4CHEK2 | |
| SCHEMBL1387244 | 0.86 | EGFR (1.00) | EGFRERBB2AURKBERBB4CHEK2 | |
| Hydrochloric Acid SCHEMBL7243031 | 0.86 | EGFR (0.77) | EGFRERBB2AURKBERBB4CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197915-A1 | LAPATINIB INTERMEDIATES | TEVA PHARMACEUTICALS USA, INC. | 2010-08-05 | — | — | US | claimed |
| WO-2010017387-A2 | LAPATINIB INTERMEDIATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2010-02-11 | — | — | WO | claimed |
| US-20160339027-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2016-11-24 | — | — | US | disclosed |
| US-20160051551-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2016-02-25 | — | — | US | disclosed |
| US-9199973-B2 | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2015-12-01 | — | — | US | disclosed |
| US-20150065527-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-03-05 | — | — | US | disclosed |
| US-8912205-B2 | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2014-12-16 | — | — | US | disclosed |
| US-20130310562-A1 | Bicyclic Heteroaromatic Compounds As Protein Tyrosine Kinase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-11-21 | — | — | US | disclosed |
| US-8513262-B2 | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-08-20 | — | — | US | disclosed |
| US-20100197915-A1 | LAPATINIB INTERMEDIATES | TEVA PHARMACEUTICALS USA, INC. | 2010-08-05 | — | — | US | disclosed |
| US-20100120804-A1 | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2010-05-13 | — | — | US | disclosed |
| CN-1134438-C | Bicyclic heteroaromatic compounds, preparation method and use thereof | �ձ���ҩ��ʽ���� | 2004-01-14 | — | — | CN | disclosed |
| US-20030176451-A1 | Reacting a heterocyclic-methanesulfonyl substituted-quinazolineamine compound with amine compound | LEO OSPREY LIMITED (GB) | 2003-09-18 | — | — | US | disclosed |
| EP-0912559-B1 | FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2002-11-06 | — | — | EP | disclosed |
| US-20020147205-A1 | Heterocyclic compounds | NOVARTIS AG (CH) | 2002-10-10 | — | — | US | disclosed |
| US-20020147214-A1 | Heterocyclic compounds | NOVARTIS AG (CH) | 2002-10-10 | — | — | US | disclosed |
| US-6391874-B1 | ANTICARCINOGENIC AGENTS; SKIN DISORDERS | SMITHKLINE BEECHAM CORPORATION | 2002-05-21 | — | — | US | disclosed |
| CN-1292788-A | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors | GLAXO GROUP LTD (GB) | 2001-04-25 | — | — | CN | disclosed |
| EP-0912559-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1999-05-06 | — | — | EP | disclosed |
| WO-1998002434-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1998-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197915-A1 | LAPATINIB INTERMEDIATES | ERBB2, ABL1, EGFR | EGFR 3/4885ERBB2 1/4885AURKB 76/4885 |
| US-20030176451-A1 | Reacting a heterocyclic-methanesulfonyl substituted-quinazolineamine compound with amine compound | CCNH, HRH2, HRH1 | EGFR 3409/4885ERBB2 2282/4885AURKB 1117/4885 |
| US-20020147205-A1 | Heterocyclic compounds | ERBB2, ERBB3, ERBB4 | EGFR 4/4885ERBB2 1/4885AURKB 369/4885 |
| US-20160339027-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | ABL1, ERBB2, SRC | EGFR 7/4885ERBB2 2/4885AURKB 109/4885 |
| US-20020147214-A1 | Heterocyclic compounds | BRAF, ABL1, CSK | EGFR 354/4885ERBB2 35/4885AURKB 175/4885 |
| US-20100120804-A1 | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors | ABL1, ERBB2, CDK2 | EGFR 69/4885ERBB2 2/4885AURKB 147/4885 |
| US-20130310562-A1 | Bicyclic Heteroaromatic Compounds As Protein Tyrosine Kinase Inhibitors | ABL1, ERBB2, SRC | EGFR 7/4885ERBB2 2/4885AURKB 109/4885 |
| US-20160051551-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | ABL1, ERBB2, SRC | EGFR 7/4885ERBB2 2/4885AURKB 109/4885 |
| US-20150065527-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | ABL1, ERBB2, SRC | EGFR 7/4885ERBB2 2/4885AURKB 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.